Purple Biotech Return on Equity (ROE) Growth & History (PPBT)

Purple Biotech's return on equity was −124.45% for fiscal 2025.

View full Purple Biotech company overview

Purple Biotech annual return on equity history

Purple Biotech annual return on equity

Fiscal yearPeriod endedReturn on equityChange (percentage points)
20252025-12-31−124.45%−102.74 pp
20242024-12-31−21.71%+27.55 pp
20232023-12-31−49.25%−10.31 pp
20222022-12-31−38.95%−64.56 pp
20212021-12-3125.61%−36.91 pp
20202020-12-3162.52%+6.24 pp
20192019-12-3156.27%−5.84 pp
20182018-12-3162.12%−62.09 pp
20172017-12-31124.21%+17.91 pp
20162016-12-31106.29%

Purple Biotech return on equity trends

Over the last five fiscal years, Purple Biotech's return on equity decreased from 62.52% to −124.45%, a change of −186.97 percentage points. The latest reported quarter, Q2 2026, shows 4.01%.

About the metric

What return on equity (ROE) means

Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.

Calculation and source

How return on equity is calculated

TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Purple Biotech source filings ↗

Community posts

It’s quiet here.

No posts about PPBT yet. Start the conversation.

Write the first post